Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Appl Immunohistochem Mol Morphol
Hauptverfasser: Cheung, Carol C., Barnes, Penny, Bigras, Gilbert, Boerner, Scott, Butany, Jagdish, Calabrese, Fiorella, Couture, Christian, Deschenes, Jean, El-Zimaity, Hala, Fischer, Gabor, Fiset, Pierre O., Garratt, John, Geldenhuys, Laurette, Gilks, C. Blake, Ilie, Marius, Ionescu, Diana, Lim, Hyun J., Manning, Lisa, Mansoor, Adnan, Riddell, Robert, Ross, Catherine, Roy-Chowdhuri, Sinchita, Spatz, Alan, Swanson, Paul E., Tron, Victor A., Tsao, Ming-Sound, Wang, Hangjun, Xu, Zhaolin, Torlakovic, Emina E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2019
Schlagworte:
Hot Topic
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://ncbi.nlm.nih.gov/pubmed/31584451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000800
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge